Context Therapeutics to Present Poster at AACR Annual Meeting

The biopharmaceutical company will highlight preclinical data on its Nectin-4 x CD3 T cell engaging bispecific antibody.

Mar. 19, 2026 at 11:51am

Got story updates? Submit your updates here. ›

Context Therapeutics Inc., a clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibodies for solid tumors, announced it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California. The presentation will highlight preclinical data on the company's asset, CT-202, a Nectin-4 x CD3 TCE bispecific antibody.

Why it matters

Context Therapeutics is working to build an innovative portfolio of TCE bispecific therapeutics to treat solid tumors. The AACR presentation will provide an opportunity for the company to share its latest preclinical findings on CT-202, which targets Nectin-4, a cell surface protein overexpressed in various solid cancers.

The details

CT-202 is a Nectin-4 x CD3 TCE bispecific antibody designed to be preferentially active within the tumor microenvironment. Nectin-4 is a clinically validated target for cancer therapy using antibody-drug conjugates, but it is also associated with certain adverse events. Context's TCE approach aims to leverage the immune system to target Nectin-4-expressing tumors while potentially minimizing the side effects seen with traditional antibody-drug conjugates.

  • The AACR Annual Meeting 2026 will take place from April 17-22, 2026 in San Diego, California.
  • Context Therapeutics announced the poster presentation on March 19, 2026.

The players

Context Therapeutics Inc.

A clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibodies for solid tumors.

CT-202

A Nectin-4 x CD3 TCE bispecific antibody developed by Context Therapeutics that targets Nectin-4, a cell surface protein overexpressed in various solid cancers.

American Association for Cancer Research (AACR)

A professional organization dedicated to advancing cancer research and discovery.

Got photos? Submit your photos here. ›

What’s next

The poster presentation on CT-202 will be made available in the Publications section of Context Therapeutics' website at the beginning of the AACR Annual Meeting 2026 poster session.

The takeaway

Context Therapeutics' participation in the AACR Annual Meeting highlights the company's commitment to advancing innovative T cell engaging bispecific antibodies as potential new treatments for solid tumors. The presentation of preclinical data on CT-202 will provide insights into the company's pipeline and its approach to targeting Nectin-4, a clinically validated cancer target.